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ABSTRACT: 
 
Canavan disease (CD) is a rare leukodystrophy characterized by diffuse spongiform 
white matter degeneration, dysmyelination and intramyelinic oedema with consequent 
impairment of psychomotor development and early death. The molecular cause of CD 
has been identified as being mutations of the gene encoding the enzyme aspartoacylase 
(ASPA) leading to its functional deficiency. The physiological role of ASPA is to 
hydrolyse N-acetyl-L-aspartic acid (NAA), producing L-aspartic acid and acetate; as a 
result, its deficiency leads to abnormally high central nervous system NAA levels. The 
aim of this article is to review what is currently known regarding the aetiopathogenesis 
of CD with emphasis on the non-genetic therapeutic strategies, both at an experimental 
and a clinical level, by highlighting: (a) major related hypotheses, (b) the results of the 
available experimental simulatory approaches, as well as (c) the relevance of the so far 
examined markers of CD neuropathology. The potential and the limitations of the 
current non-genetic neuroprotective approaches to the treatment of CD are particularly 
discussed in the current article, in a context that could be used to direct future 
experimental and (eventually) clinical work in the field. 
 
List of abbreviations: Ac: acetate; Acetyl-CoA: acetyl-coenzyme A; ACS: acetyl-
coenzyme A synthetase; Asp: L-aspartic acid; ASPA: aspartoacylase; AspNAT: 
aspartate N-acetyltransferase; BBB: blood-brain barrier; CA: calcium acetate; CD: 
Canavan disease; CNS: central nervous system; CoA: coenzyme A; ECF: extracellular 
fluid; Gln: glutamine; Glu: glutamate; GMR3: metabotropic glutamate receptor 3 
(mGluR3); GTA: glyceryl triacetate; HPLC: high-performance liquid chromatography; 
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Li: lithium; LiCl: lithium chloride; Li3C6H5O7: lithium citrate; MRI: magnetic 
resonance imaging; MRS: magnetic resonance spectroscopy; NAA: N-acetyl-L-aspartic 
acid or N-acetylaspartate; NAAG: N-acetylaspartylglutamic acid; NPCs: neural 
progenitor cells; TCA: tricarboxylic acid.    
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Introduction 
 
Canavan disease (CD) is a rare leukodystrophy characterized by diffuse spongiform 
white matter degeneration, dysmyelination and intramyelinic oedema with consequent 
impairment of psychomotor development and early death (Hoshino and Kubota, 2014; 
Kumar et al., 2006; Matalon and Michals-Matalon, 1999a). Globus and Strauss (1928) 
were the first to recognise the spongy deteriorative effects of the disease, although the 
first clinical description was provided by Myrtelle Canavan (Canavan, 1931). Almost 
two decades later, Van Bogaert and Bertrand (1949) reported its autosomal recessive 
nature and increased prevalence amongst Ashkenazi Jewish population; notably, CD is 
also known as the “Canavan-Van Bogaert-Bertrand” disease. The molecular cause of 
CD was identified many years later (Matalon et al., 1988) as the presence of mutations 
within the gene encoding the enzyme aspartoacylase (ASPA; EC 3.5.1.15; N-acetyl-L-
aspartate amidohydrolase) located on the short arm of chromosome 17 (17p13.3). 
However, since the purification and characterization of ASPA (Kaul et al., 1991) and 
the cloning of the human ASPA cDNA (Kaul et al., 1993), over 54 loss-of-function 
mutations have been identified (Kaul et al., 1993; Stenson et al., 2003). Only two point 
mutations are responsible for 98% of the Ashkenazi Jewish cases (Glu285Ala and 
Tyr231X), while other (non-Ashkenazi Jewish) cases may result from a range of 
mutations (Michals and Matalon, 2011; Zayed, 2015). The physiological role of ASPA 
is to hydrolyse N-acetyl-L-aspartic acid (NAA), producing (e.g. in oligodendrocytes) L-
aspartic acid (Asp) and acetate (Ac) (see Figure 1 for more details); as expected, its 
deficiency leads to abnormally high central nervous system (CNS) NAA levels (>35%) 
(Janson et al., 2006b), with vast amounts of NAA being excreted in urine (N-
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acetylaspartic aciduria). It should be noted that urinary NAA levels are 10-100 fold 
higher in CD patients than age-matched healthy subjects, and this is the preferred 
method of CD diagnosis (Hagenfeldt, 1987). 
Three forms of CD have been distinguished, differing in symptom onset and 
severity: (a) the “congenital form” (severest and symptoms appear within weeks of 
life), (b) the “infantile form” which is most common (also severe, with an onset of 2-6 
months) and (c) the “juvenile form” (mildest and symptoms begin by the age of 5) 
(Adachi et al., 1973; Baslow and Resnik, 1997). Early symptoms of the disease 
include irritability, lack of head control and hypotonia, while as the disease progresses 
macrocephaly develops and developmental delays (particularly in motor and verbal 
skills) are noted, becoming increasingly apparent with age (Matalon and Michals-
Matalon, 2000). At later stages some infants may come to suffer from blindness due to 
optic atrophy, hypotonia can evolve into spasticity, voluntary movements (including 
swallowing) often become impossible and seizures may occur (Gascon et al., 1990; 
Matalon et al., 1995). Although patients with some milder forms live beyond the age 
of 20, the majority of CD patients do not reach adolescence (Hoshino and Kubota, 
2014). 
Neuropathologically, CD is an encephalitis periaxialis diffusa (Baslow, 2000) 
where: (i) the failure of the white matter-seated oligodendrocytes to myelinate the local 
neuraxons leaves the latter intact but unsheathed (and, thus, underfunctioning), and (ii) 
the white matter bears a characteristic spongy degeneration due to the development of 
swelling (oedema) and the formation of multiple intramyelinic and extracellular fluid 
vacuoles (Leone et al., 1999). The vacuoles are empty, can measure up to 200 μm and 
are primarily spotted subcortically; the deep white matter and the superficial cortex are 
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less affected. Macroscopically, the brain usually appears to be heavier than expected, 
and bears a soft, gelatinous white matter. Microscopically, CD patients’ brains are 
characterized by: (i) splits in the myelin lamellae and (ii) astrocytic swelling (evident 
both in the perikaryon and the processes) accompanied by elongated mitochondria 
(Adornato et al., 1972; Kumar et al., 2006; Matalon and Michals-Matalon, 1999b; 
Surendran et al., 2003)1. 
The aim of this mini-review article is to provide an overview of the currently-
available knowledge on the aetiopathogenesis of CD with emphasis on the current non-
genetic approaches to its treatment at both an experimental and a clinical level, by 
highlighting: (a) the major related hypotheses, (b) the results of the available 
experimental simulatory approaches, as well as (c) the relevance of the so far 
examined markers of CD neuropathology. In particular, the potential and the 
limitations of the current non-genetic neuroprotective approaches to the treatment of 
CD are particularly discussed in the current article, in a context that could be used as a 
basis for a redrafting of both future experimental and (eventually) clinical work in the 
field. 
 
Hypotheses on the pathogenesis of CD 
 
Various hypotheses have attempted to explain how the lack of ASPA activity results in 
the neurodegeneration and oedema seen in CD. One of them, the “Ac-lipid-myelin” 
hypothesis (Table 1) proposes that deficiency in NAA-derived Ac impedes myelin 
lipid synthesis (Baslow and Guilfoyle, 2013; Hagenfeldt et al., 1987). Although the 
                                                          
1 for more details on the apparent oligodendrocyte number increase in the areas of dysmyelination, the 
phenotype of the astrocytic (Alzheimer Type 2) populations and the vacuole formation, readers are 
referred to the review article of Kumar et al. (2006). 
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incorporation of acetyl moieties from NAA into myelin lipids has been observed 
(D’Adamo and Yatsu, 1966), it is believed to be involved in - but not being essential to 
- myelination, due to documentation of rare cases of CD where ASPA does not 
function yet myelination proceeds as normal (Janson et al., 2006a; Velinov et al., 
2008). However, it should be noted that experimental evidence has suggested that 
ASPA is predominantly expressed in oligodendrocytes (Madhavarao et al., 2004) and 
that the developmental expression pattern of the ASPA gene in the postnatal rat brain 
closely correlates with myelination in the CNS (Kirmani et al., 2003). 
A second hypothesis is the “osmotic-hydrostatic” hypothesis (Table 1), which 
suggests that NAA cycling between brain cells acts as a molecular water pump, 
removing metabolic water from neurons (Baslow et al., 1999). Once produced, NAA 
exists in a complex with 32 water molecules and a cation (Baslow, 2003); when 
depolarised, neurons in grey matter have been shown to release this NAA complex into 
the surrounding extracellular fluid (ECF), thus transporting water against its gradient 
(Sager et al., 1997). In a healthy subject, this complex rapidly diffuses into 
oligodendrocytes where it undergoes hydrolysis and water molecules are released 
(Wang et al., 2007); this free water then diffuses down its concentration gradient into 
the vasculature (Vajda et al., 1999). However, in CD patients, the NAA-water complex 
is still released upon neuronal depolarisation, but is not cleared from the ECF and 
instead diffuses into the vasculature (which has restricted permeability to hydrophilic 
molecules) (Redzic, 2011). The NAA-water complex builds up in the ECF which 
could lead to changes in local osmotic pressure. If a similar NAA cycle disruption 
occurs in white matter, the resulting osmotic pressure changes could account for the 
CD-related osmotic pathologies (Baslow and Guilfoyle, 2013). Although the 
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depolarisation of white matter neurons has not been documented to cause NAA release 
into the ECF, it has been suggested that the N-acetylaspartylglutamic acid (NAAG) 
released from neurons (Figure 1) could provide a source of NAA in this case (Baslow 
and Guilfoyle, 2013). It is known that NAAG-peptidase within the astrocyte end feet at 
the nodes of Ranvier hydrolyzes NAAG to produce NAA; this is the proposed source 
of NAA for white matter oligodendrocytes. However, in white matter, the limited 
extracellular space at nodes means that a potential failure of oligodendrocyte removal 
of NAA and its consequent accumulation will likely have severe osmotic 
consequences that could explain vacuole formation and the observed splitting between 
myelin sheath layers (Baslow and Guilfoyle, 2013). 
A very recent third hypothesis, proposed by Francis et al. (2012), is that 
disruption to NAA catabolism during key myelination stages in early development 
causes oxidative stress in myelinating oligodendrocytes resulting in dysmyelination 
and other CD-related pathologies. In this “oxidative stress” hypothesis (Table 1), NAA 
is suggested to reduce oxidative stress by preventing the coupling of fatty acid 
synthesis to oxidative energy metabolism through the provision of Ac. The latter can 
be converted to acetyl-coenzyme A (Acetyl-CoA) by acetyl-coenzyme A synthetase 
(ACS; Figure 1.c). Oxidative stress was shown to precede dysmyelination in nur7 mice 
(Francis et al., 2012) and, even more recently, Francis et al. (2014) supported their 
hypothesis by showing that reduction of oxidative stress by triheptanoin administration 
(which increases Krebs cycle intermediates) was shown to alleviate CD-related 
pathologies.  
 
Therapeutic approaches to CD 
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Due to uncertainty concerning causative mechanisms, CD is currently incurable, with 
available therapies being only palliative. Non-genetic treatment is focused principally 
on (a) the provision of adequate hydration and nutrition by gastronomy and nasogastric 
feeding, (b) the use of anticonvulsants to minimise seizures (Hoshino and Kubota, 
2014) and (c) the reduction of intracranial pressure using acetazolamide (Matalon and 
Michals-Matalon, 2000). Research into possible therapies, including lithium (Li) 
supplementation, Ac-supplementation, stem cell replacement and gene therapy will be 
discussed in this article, with a focus on non-genetic approaches.   
The aim of gene therapy in CD treatment is to restore ASPA activity through 
ASPA gene insertion. This approach has seen a degree of success in improving the 
major disease symptoms; however, progress is still to be made. The use of liposome 
encapsulated plasmids and adeno-associated viruses as vectors to insert the ASPA gene 
into CD mice, tremor mice and human CD subjects has resulted in enhanced ASPA 
production and activity and, in some cases, reduced CNS NAA levels and improved 
spongiform degeneration (Ahmed et al., 2013; Klugmann et al., 2005; Leone et al., 
2000; Leone et al., 2012; McPhee et al., 2005). However, it must be noted that in some 
cases the observed decrease in NAA and spongiform pathology is transient (Leone et 
al., 2012), while in others the effects are limited within a confined area surrounding 
the region of intracerebral injection (Leone et al., 2000; 2012). Improved motor 
function was noted in certain cases (Ahmed et al., 2013; Leone et al., 2012; McPhee et 
al., 2005), but not in all (Klugmann et al., 2005). Moreover, where motor defects were 
improved, they did not disappear altogether and were shown in a longitudinal study to 
relapse later in life (Ahmed et al., 2013). However, one pathologic marker of the 
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disease, early lethality, was entirely rescued by Ahmed et al. (2013) when single 
intravenous injections of primate-derived adeno-associated viruses carrying the human 
ASPA gene were administered as late as postnatal day 20 (P20) in short-lived ASPA-/- 
mice; a fact that is certainly a significant step forward towards a gene-replacement-
mediated treatment of CD.  
 
Non-genetic therapeutic approaches to CD 
 
The majority of the non-genetic strategies towards CD treatment employed to date 
have focused on addressing either the accumulation of NAA throughout the CNS or 
the deficit in metabolites which results from impaired NAA hydrolysis (Figure 1). 
Both issues have been implicated in the pathological phenotype of CD, namely 
osmotic-mediated pathologies and dysmyelination. A synopsis of the major 
compounds tested as a non-genetic therapeutic approach to CD at an experimental 
and/or clinical level is provided in Table 2. 
 
Reduction of CNS NAA levels 
 
Those believing pathogenesis in CD to result principally from NAA accumulation in 
the CNS through mechanisms such as disrupted osmoregulation, have looked for 
substances that could reverse the observed CD pathology by lowering CNS NAA 
levels, determined through high-performance liquid chromatography (HPLC) analysis. 
Whilst experimental studies have identified ethanol (Baslow et al., 2000; Hirakawa et 
al., 1994), sodium valproate (O’Donnell et al., 2000) as well as pyrazole and a number 
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of its derivatives2 (Baslow et al., 2000) to be potential candidates due to their ability to 
reduce NAA levels in non-diseased animal brains, when these compounds were tested 
in a CD animal model, no significant reductions were observed (Baslow et al., 2002) 
(Table 2). In this case, the CD-simulating animal model used was the CD-like tremor 
rat, which possesses a CD-like syndrome as a result of a naturally-occurring deletion 
of the ASPA gene (Kitada et al., 2000).  
To date, the only substance that has persistently decreased CNS NAA levels in 
both animals and humans, diseased as well as non-diseased, is Li in both the form of Li 
chloride (LiCl) and Li citrate (Li3C6H5O7)3. O’Donnell et al. (2000) have shown LiCl 
to reduce brain NAA levels by 9% when given to rats at a daily dosage of 170 mg/kg 
of body weight for 2 weeks, but it was Baslow et al. (2002) that highlighted its 
potential therapeutic value in CD and tested it on CD-like tremor rats (Table 2). A 13% 
reduction in brain NAA levels was measured through HPLC analysis of CD-like 
tremor rat CNS samples following administration of LiCl at a dose of 300 mg/kg of 
body weight, daily for 4 days (Baslow et al., 2002). Interestingly, Li3C6H5O7 was later 
tested on a human CD patient (Janson et al., 2005) and achieved statistically-
significant reduction of NAA levels in only one of the four CNS regions studied; 
nonetheless, NAA levels declined in all studied CNS regions in both the white and the 
grey matter, as measured through proton magnetic resonance spectroscopy (MRS) 
studies. The 18-month-old female CD patient ingested Li3C6H5O7 to up to 45 mg/kg of 
                                                          
2 more specifically, the following (pyrazole-deriving) compounds which are known inhibitors of alcohol 
dehydrogenase: 4-pyrazolecarboxylic acid, 1-H-pyrazole-1-carboxamidine-HCl, 4-methypyrazole and, 
pyrazole-3,5-dicarboxylic acid monohydrate. 
3 readers are reminded that Li compounds are used as mood stabilizing agents; their action is not yet 
characterized by a specific biochemical mechanism, but recent evidence suggests that Li might exert 
neuroprotection through a concentration of mitochondrial dysfunction (Malhi et al., 2013); a potential 
reason for its herein discussed effectiveness in CD.  
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body weight per day for 4 months and her magnetic resonance imaging (MRI) scans 
showed that T1 changes in white matter showed greater similarity to age-matched 
values for healthy human subjects (compared with theoretical values for CD patients), 
suggesting that myelination was more normal as a result of the Li-treatment (Janson et 
al., 2005). Her clinical symptoms also appeared mildly improved, as the patient 
showed increased awareness of her surroundings, increased alertness and minor 
improvements in language and gross motor function (Janson et al., 2005).  
A second human study on a cohort of six patients and over a time period of 60 
days (Assadi et al., 2010), showed Li3C6H5O7 to be non-toxic at the same dosage (45 
mg/kg per day), demonstrated a statistically-significant drop in NAA levels in the 
basal ganglia (through proton MRS) and indicated a mildly improved myelination in 
the frontal white matter (from MRI T1 relaxation times). Improved alertness and social 
interactions were also noted, while gross motor function testing on the other hand 
failed to show any statistically-significant improvement (Assadi et al., 2010).  
In a more recent case report (Solsona et al., 2012), Li3C6H5O7 was again 
reported to lower CNS NAA levels when given to a 3-month-old female CD patient for 
a year at a dosage of 45 mg/kg per day: a 20% reduction of CNS NAA levels was 
achieved and the substance was again well-tolerated. Moreover, alertness and visual 
tracking were reported to have improved, but hypotonia and spasticity remained 
(Solsona et al., 2012).  
In all cases (Table 2), any symptomatic improvements from Li-administration 
were mild, but results were consistent and no adverse effects were reported following 
intake for up to a year. It is possible that higher dosages might be required to see 
greater therapeutic benefit; therefore studies on the safety of higher Li dosages in 
13 
 
animals might be a beneficial prerequisite prior to any clinical attempt. The 
mechanism by which Li lowers CNS NAA levels is unknown4. It has been suggested 
to prevent NAA release from neurons or increase expulsion from the CNS by affecting 
blood-brain barrier (BBB) permeability (Janson et al., 2005). An alternative 
mechanism that could be targeted is inhibition of the NAA synthetic pathways (Baslow 
and Guilfoyle, 2009). The latter could either be accomplished by competitive or 
irreversible inhibition of aspartate N-acetyltransferase (AspNAT; the enzyme that 
synthesises NAA from Asp and Acetyl-CoA) (Figure 1.c) or by inhibiting NAAG-
peptidase in order to prevent NAA synthesis from NAAG hydrolysis; the latter is 
further discussed below.  
 
Water removal 
 
Baslow and Guilfoyle (2013) have recently proposed that maintenance of a sustained 
increase in plasma NAA levels in CD patients, by oral NAA-administration, might be 
therapeutic as a means of reducing oedema and other osmotic brain pathologies seen in 
the disease. Baslow and Guilfoyle (2013) claim that NAA accumulation in plasma 
would increase plasma oncotic pressure, and since NAA is thought to be unable to pass 
through the BBB, an outward water gradient from the CNS ECF to the vasculature 
should be established and water should exit the brain. However, studies have yet to be 
carried out to test this hypothesis.  
 
Accumulation of NAA and oxidative stress 
 
                                                          
4 it is worth noting that recent experimental studies have shown that Li can enhance remyelination of 
peripheral nerves (Makoukji et al., 2012) and influence white matter microstructure (Benedetti et al., 
2013) by (probably) acting as a glucogen synthase kinase 3-beta (GSK3-β) inhibitor. 
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Due to evidence that CNS NAA accumulation may be damaging through its initiation 
of oxidative stress (Pederzolli et al., 2007; 2009; Surendran and Bhatnagar, 2011), 
antioxidants have been considered as a potential treatment for CD. Lipoic acid, being 
known to cross the BBB and to have a high potency, was tested in its ability to reduce 
signs of NAA-induced oxidative stress in 14-day-old Wistar rats (Pederzolli et al., 
2010): when given before acute NAA-administration (40 mg/kg of body weight, 
intraperitoneally, 2-days prior to NAA), all signs of oxidative stress induced by NAA 
were prevented. Whereas rats that received NAA alone showed increased lipid 
peroxidation, protein oxidation and DNA damage and decreased enzymatic and non-
enzymatic defences, none of these effects were seen in rats pre-treated with lipoic acid 
(Pederzolli et al., 2010). These results suggest that dietary supplementation with lipoic 
acid could be a worthwhile approach to the treatment of CD, but further studies must 
first produce evidence of symptomatic improvements in more appropriate CD animal 
models.   
 
Supplementation of Ac 
 
Other studies have focused on the “Ac-myelin-lipid” hypothesis and attempted to 
restore myelination through Ac-supplementation (Arun et al., 2010; Madhavarao et al., 
2009; Mathew et al., 2005; Namboodiri et al., 2006; Segel et al., 2011) (Table 2). To 
this end, calcium Ac (CA) and glyceryl triacetate (GTA) have both been tested in their 
ability to deliver Ac to the CNS (Mathew et al., 2005; Namboodiri et al., 2006). 
Intragastric administration of equivalent amounts of CA or GTA to 21-day-old 
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C57BL/6 mice showed GTA to raise CNS Ac levels much more effectively5 and to 
have fewer adverse effects than CA, although both were found to be reasonably safe 
(Mathew et al., 2005; Namboodiri et al., 2006).  
A few years later, GTA was shown to be safe when orally administered in low 
doses to CD infant patients and in high doses to tremor rat pups, although not 
efficiently alleviating the CD-associated symptomatology in the human trial 
(Madhavarao et al., 2009). A later study (Arun et al., 2010) on the tremor rats reported 
increased CNS galactocerebroside6 levels, decreased spongy vacuolation and improved 
motor performance were noted due to high-dose administration of GTA. Moreover, 
once again, the treatment was well-tolerated as no toxic effects were reported (Arun et 
al., 2010).  
Given the successful tolerance of GTA at high dosage in rats, high-dose tests 
(4.5 g/kg of body weight per day) were carried out on 8-month- and 1-year-old CD 
infants over a period of 4.5 and 6 months respectively, throughout which time neither 
toxicity nor motor improvements were observed (Segel et al., 2011). The latter was 
attributed to the late onset of treatment (Segel et al., 2011). Moreover, it should be 
noted that at its highest dosage so far trialled, GTA has shown limited benefit in 
humans (Table 2), while treatment at an earlier age could lead to improved symptoms 
(as was seen in tremor rats) and should be considered when designing future studies.  
 
Energetic substrates  
                                                          
5  it has been reported that when equimolar concentrations of GTA and CA were administered 
(intragastrically) to mice, CNS Ac levels were found to be higher in the GTA-fed mice; a finding 
suggested to reflect the ability of the hydrophobic GTA to easier penetrate cell membranes (Mathew et 
al., 2005; Namboodiri et al., 2006). 
6 galactocerebroside (or galactosylceramide) is a critical CNS myelin-associated lipid that is recognised 
as an oligodendrocytic marker and that is found to be specifically-reduced in the CD-like tremor rat 
(Wang et al., 2009). 
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Another dietary supplement proposed for use as a non-genetic therapeutic approach to 
CD is the anaplerotic triglyceride “triheptanoin”. Building on the earlier observation 
that deficient NAA hydrolysis causes acute oxidative stress by increasing the coupling 
of fatty acid synthesis to oxidative energy metabolism (Francis et al., 2012), Francis et 
al. (2014) attempted to restore oxidative integrity through provision of alternative 
substrates for energy production. In that study, nur7 mouse mutants in their last week 
of prenatal life and 2-week-old nur7 pups were fed a chow containing 35% (as caloric 
composition) triheptanoin until 12-weeks of age, and analysis of the animals’ brains at 
12-weeks showed oxidative stress, oligodendrocyte loss and dysmyelination to have 
been markedly reduced, while performance on accelerating rotarod testing at this age 
suggested improved motor function (Francis et al., 2014) (Table 2). Notably, earlier-
treated mice showed the greatest improvements in all aforementioned parameters 
(Francis et al., 2014). However, it is not yet known how triheptanoin supplies 
substrates to oligodendrocytes, but triheptanoin was chosen based on its ability to 
produce TCA cycle intermediates whilst also providing substrates for lipogenesis. 
 
Cell therapy 
 
Since oligodendrocytes are an important source of CNS ASPA (Bhakoo et al., 2001), 
if not the most important (Baslow et al., 1999; Kirmani et al., 2002; 2003; Klugmann 
et al., 2003; Mhadavarao et al., 2002; 2004), repopulation of the brain of a CD patient 
with functional oligodendrocytes could potentially rectify much of the disease 
phenotype through the restoration of normal NAA metabolism. Neural stem cells have 
been successfully used to generate oligodendrocytes in the CD mouse model 
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(Surendran et al., 2004) and these oligodendrocytes expressed a myelin-specific 
enzyme indicative of myelin-producing ability, but clinical outcomes of such a 
treatment have yet to be investigated. Although the survival rate of neural progenitor 
cells (NPCs) was generally high in the juvenile treated mice (Surendran et al., 2004), 
the migration of these cells was limited, suggesting that much progress has to be made 
before any results (if seen) will be widespread enough to impact upon the brain 
pathology of this condition. In addition to the migratory potential, the stability 
(Amariglio et al., 2009) and safety of transplanted and differentiated NPCs in the CD 
mice CNS remains to be proven, while acquiring sufficient quantities of NPCs for 
human transplantation is likely to be difficult (Miranda et al., 2013).  
The NPCs used in the aforementioned study (Surendran et al., 2004) were also 
tested on their ability to act as vectors for ASPA gene therapy. After 4 weeks of 
transplantation, enzyme activity assays carried out on juvenile CD mice showed ASPA 
activity to be 16% of that measured in wild-type mice (Surendran et al., 2004). 
However, this activity was shown to decline in the adult mice 5 weeks after the 
transplantation, perhaps due to the short-term expression of the retroviral vector 
pLXIN in vivo (Surendran et al., 2004); one should note that the use of adeno-
associated virus vectors has been suggested to increase long-term efficacy of treatment. 
Although further studies should be carried out in order to clarify whether ASPA 
activity can be sufficiently increased through this method for there to be any 
phenotypic improvements in CD mouse models, yet again safety, stability and 
migration of NPCs will still need to be considered.  
 
Novel pharmaceutical approaches 
 
18 
 
The anti-convulsant “topiramate” was found to decrease the velocity of head growth in 
two CD patients following its administration for 7 and 15 months, beginning at 6-
months of age in both children (Topçu et al., 2004). The mechanisms responsible for 
this effect are not certain, but Topçu et al. (2004) suggested that CNS water 
accumulation was reduced, perhaps involving carbonic anhydrase inhibition. Although 
the benefit of topiramate is very minor to CD patients, if the underlying mechanisms 
by which it acts are elucidated, more light might be shed upon the pathological basis of 
the disease and might be supportive of the aforementioned “osmotic-hydrostatic” 
hypothesis. 
 
Blocking of NAAG catabolism 
 
Considering the hypothesis that an important amount of NAA accumulating within the 
white matter of CD patients could derive from NAAG catabolism, Baslow and 
Guilfoyle (2009) have suggested that the use of NAAG-peptidase inhibitors or of 
metabotropic glutamate receptor 3 (GRM3 or mGluR3; the natural astrocytic surface 
target for NAAG) 7 agonists and antagonists (Baslow, 2008) could slow down the 
dysmyelination process. 
 
Conclusion 
 
There are still many aspects of the pathophysiology of CD that need to be clarified. 
Although the intracerebral NAA accumulation and dysmyelination appear to be the 
major regulators of the disease’s progress and phenotype, experimental evidence 
                                                          
7 GRM3 and NAAG-peptidase are actually a complex reported to appear particularly in the white matter 
astrocytic cells (Baslow, 2008; Baslow and Guilfoyle, 2009; Fotuhi et al., 1994). 
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suggests that CD mutations might have broader deregulating impacts on the 
developing CNS (Kumar et al., 2006).  
It is without doubt that an efficient gene therapy for CD would be an ideal 
treatment approach if applied at a very early age. As such an approach still needs to be 
addressed through the manufacturing of long-time expression effective vectors 
(Surendran et al., 2006), some degree of near-term management of CD must be 
considered through NAA synthesis-blockage or NAA removal from the patients’ CNS. 
To-date, the only non-genetic approach to the treatment of CD that has generated 
evidence towards a clinical improvement in CD patients is Li-supplementation. 
Interestingly, while drafting this article, Guo et al. (2015) have provided a very 
important study in support of the “osmotic-hydrostatic” theory (for which Li-
supplementation appears as a therapeutic option). On the other hand, the 
supplementation of Ac through GTA has shown promise when in animal tests, but as 
of yet fails to achieve clinical improvements in human studies, perhaps due to late 
onset of the attempted treatment (Table 2).  
Notably, early intervention has consistently shown to produce better results in 
all forms of treatment, supporting the theories that implicate disruption to early 
developmental myelination in the pathogenesis of CD. Targeting of oxidative stress 
seems likely to have a therapeutic benefit but clinical studies in these areas are still 
lacking. Future attempts incorporating larger cohorts, longer periods of analysis and 
wider dose schemes (especially in the case of studies focused on Li- and Ac-
supplementation) could provide more conclusive evidence of the therapeutic benefit of 
these approaches. Due to the rarity of the disease, the launching of a multicentre 
coordination initiative might be necessary in order to achieve larger cohort studies in a 
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timely manner. However, even if such attempts do reach successful outcomes and 
produce a considerable clinical benefit, the course of the disease might not be fully 
obstructed until the problem is addressed at the axon-myelinating oligodendrocyte 
interface. 
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Table 1. Overview of the current three hypotheses proposed for the pathogenesis of 
Canavan disease (CD), their mechanism(s) and the neuroprotective approaches that 
could prove effective in each case. 
 
  
Hypothesis Outline of the mechanism(s) and potential neuroprotectant(s) 
  
  
Ac-lipid-myelin − in CD patients, deficiency in NAA-derived Ac results in impeded 
myelin lipid synthesis in oligodendrocytes 
− potential therapeutic approach: CA, GTA 
  
osmotic-hydrostatic − NAA cycling between brain cells acts as a molecular water pump 
− in CD patients, the NAA-water complex builds up in the ECF, 
leading to changes in local osmotic pressure 
− in the white matter of CD patients, the limited extracellular space 
at nodes means that a potential failure of oligodendrocyte removal 
of NAA (and its consequent build up) is likely having severe 
osmotic consequences that could explain vacuole formation and 
the observed splitting between myelin sheath layers 
− potential therapeutic approach: ethanol, LiCl, Li3C6H5O7, NAA, 
pyrazole and its derivatives, sodium valproate, topiramate 
  
oxidative stress − in CD patients, disruption to NAA catabolism during key 
myelination stages in early development causes oxidative stress in 
myelinating oligodendrocytes, resulting in dysmyelination and 
other CD-related pathologies 
− potential therapeutic approach: lipoic acid, triheptanoin 
  
 
Note: the use of topiramate as a potential therapeutic approach to CD within the “osmotic-hydrostatic” 
hypothesis is still to be clarified / confirmed. Abbreviations used: Ac: acetate; CA: calcium acetate; ECF: 
extracellular fluid; GTA: glyceryl triacetate; Li: lithium; LiCl: lithium chloride; Li3C6H5O7: lithium 
citrate; NAA: N-acetyl-L-aspartic acid or N-acetylaspartate; TCA: tricarboxylic acid.  
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Table 2. Synoptic presentation of the major experimental and/or clinical studies (if any) on the efficacy of potential therapeutic 
compounds for Canavan disease (CD). 
 
   
Compound name Chemical structure Major experimental and/or clinical studies and their findings  
   
   
N-Acetyl-L-aspartate 
(NAA) 
 
− hypothesis of use: “osmotic-hydrostatic” 
− specific aim: increase of plasma NAA levels as a means of increasing plasma 
oncotic pressure and generating an outward water gradient from the CNS ECF to 
the vasculature; suggestion made by Baslow and Guilfoyle (2013) 
− experimental study: --- 
− human trial: --- 
   
Calcium acetate 
(CA)  
− hypothesis of use: “Ac-lipid-myelin” 
− specific aim: Ac-supplementation towards restoration of myelination 
− experimental study: Mathew et al. (2005); Namboodiri et al. (2006) 
− major finding(s): increased CNS Ac levels in C57BL/6 mice; less efficient than 
GTA 
   
Ethanol  − hypothesis of use: “osmotic-hydrostatic” 
− specific aim: reduction of CNS NAA levels 
− experimental study: Baslow et al. (2000) 
− major finding(s): reduction of CNS NAA levels in healthy Swiss-Webster mice 
− experimental study: Baslow et al. (2002) 
− major finding(s): unable to reduce CNS NAA levels in CD-like tremor rats 
   
Glyceryl triacetate 
(GTA) 
 
− hypothesis of use: “Ac-lipid-myelin” 
− specific aim: Ac-supplementation towards restoration of myelination 
− experimental study: Mathew et al. (2005); Namboodiri et al. (2006) 
− major finding(s): increased CNS Ac levels in C57BL/6 mice; more efficient than 
CA 
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− experimental study: Madhavarao et al. (2009) 
− major finding(s): no detectable toxicity due to high-dose GTA administration in 
tremor rats 
− experimental study: Arun et al. (2010) 
− major finding(s): increased CNS galactocerebroside levels, decreased spongy 
vacuolation and improved motor performance in tremor rats due to high-dose 
administration of GTA 
− human trial: Madhavarao et al. (2009) 
− subject(s): two CD patients (8- and 13-month-old) 
− major finding(s): no change in CNS NAA levels, no observable pathological 
changes over the course of the treatment, stabilization of clinical condition 
without improvement 
− human trial: Segel et al. (2011) 
− subject(s): two CD patients (8-month- and 1-year-old) 
− major finding(s): no clinical improvement, good tolerance of the high dose 
   
Lipoic acid 
 
− hypothesis of use: “oxidative stress” 
− specific aim: reduction of NAA-induced oxidative stress; crossing of the BBB 
− experimental study: Pederzolli et al. (2010) 
− major finding(s): reduction of NAA-induced oxidative stress-related changes in 
the Wistar rat CNS through pretreatment with lipoic acid 
   
Lithium chloride 
(LiCl)  
− hypothesis of use: “osmotic-hydrostatic” 
− specific aim: reduction of CNS NAA levels / unknown mechanism 
− experimental study: O’Donnell et al. (2000) 
− major finding(s): reduction of CNS NAA levels in healthy Sprague-Dawley rats 
− experimental study: Baslow et al. (2002) 
− major finding(s): reduction (-13%) of CNS NAA levels in CD-like tremor rats 
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Lithium citrate 
(Li3C6H5O7) 
 
− hypothesis of use: “osmotic-hydrostatic” 
− specific aim: reduction of CNS NAA levels / unknown mechanism 
− human trial: Janson et al. (2005) 
− subject(s): 18-month-old female CD patient 
− major finding(s): reduction of CNS NAA levels, improved myelination, mild 
clinical improvement 
− human trial: Assadi et al. (2010) 
− subject(s): cohort of six CD patients (average age: 9.5 months) 
− major findings: reduction of basal ganglia NAA levels, mildly improved 
myelination in frontal white matter, partial clinical improvement 
− human trial: Solsona et al. (2012) 
− subject(s): 3-month-old female CD patient 
− major finding(s): reduction (-20%) of CNS NAA levels, partial clinical 
improvement 
   
Pyrazole and derivatives 
 
− hypothesis of use: “osmotic-hydrostatic” 
− specific aim: reduction of CNS NAA levels 
− experimental study: Baslow et al. (2000) 
− major finding(s): reduction of CNS NAA levels in healthy Swiss-Webster mice 
− experimental study: Baslow et al. (2002) 
− major finding(s): unable to reduce CNS NAA levels in CD-like tremor rats 
   
Sodium valproate 
 
− hypothesis of use: “osmotic-hydrostatic” 
− specific aim: reduction of CNS NAA levels 
− experimental study: O’Donnell et al. (2000) 
− major finding(s): reduction of CNS NAA levels in healthy Sprague-Dawley rats 
− experimental study: Baslow et al. (2002) 
− major finding(s): unable to reduce CNS NAA levels in CD-like tremor rats 
   
Topiramate 
 
− hypothesis of use: “osmotic-hydrostatic” / to be clarified 
− specific aim: presumably involving reduced CNS water accumulation due to 
carbonic anhydrase inhibition 
− human trial: Topçu et al. (2004) 
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− subject(s): two CD patients (13- and 21-month-old) 
− major finding(s): decline in head growth velocity (as a measure of 
megalencephaly progression) 
   
Triheptanoin 
 
− hypothesis of use: “oxidative stress” 
− specific aim: support of oxidative integrity, providing of ketone bodies capable of 
crossing of the BBB 
− experimental study: Francis et al. (2014) 
− major finding(s): reduction of CNS oxidative stress, increased thalamic myelin 
levels and cortical oligodendrocyte survival, reduced spongiform degeneration as 
well as improved motor function in nur7 mice 
   
 
Abbreviations used: Ac: acetate; BBB: blood-brain barrier; CNS: central nervous system; ECF: extracellular fluid. 
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Legend to the Figure: 
 
Figure 1. Overview of the metabolic pathway of N-acetyl-L-aspartate (NAA) within 
the human central nervous system. (a, b): The synthesis of NAA occurs in neuronal 
mitochondria (1) and, from there, NAA is transported out of the mitochondria via a 
putative NAA-transporter and released from neurons or transported to 
oligodendrocytes at the junction of the neuraxon with the inner plasma membrane of 
the myelin sheaths (2). The NAA reaching the oligodendrocytes is used for fatty acid / 
myelin lipid synthesis and energy production. On the other hand, neuronal NAA could 
also combine with glutamate (Glu) to produce N-acetylaspartylglutamate (NAAG) (1). 
The latter is co-released from synaptic vesicles along with several neurotransmitters 
and can act on the astrocytic metabotropic glutamate receptor 3 (GRM3 or mGluR3) or 
be hydrolyzed at the surface of astrocytes to NAA and Glu (3). In the astrocytes, Glu 
can combine with ammonia to produce glutamine (Gln) (4). Neurons can uptake Gln 
(5) and use it as a source of Glu, while both astrocytic NAA and Gln can be released to 
the general circulation (6). (c): Schematic overview of NAA synthesis and metabolism 
in neurons and oligodendrocytes. In neuronal mitochondria, pyruvate (Pyr) undergoes 
decarboxylation by the pyruvate dehydrogenase (PDH) complex and produces acetyl-
coenzyme A (Acetyl-CoA). The latter can either be introduced to the tricarboxylic acid 
cycle (TCA cycle or Krebs cycle) or be combined with L-aspartic acid (Asp) to 
synthesize NAA via aspartate N-acetyltransferase (AspNAT). One NAA is transferred 
out of the neuronal mitochondrion, it can either be used to synthesize NAAG, to be 
released from the neurons or to be transferred to the oligodendrocytes. In the 
oligodendrocytes, NAA is hydrolyzed by aspartoacylase (ASPA; the enzyme whose 
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deficiency is considered as the causing factor for Canavan disease) to produce Asp and 
acetate (Ac). The latter can be converted to Acetyl-CoA by acetyl-coenzyme A 
synthetase (ACS) which in turn can provide a substrate for the synthesis of fatty acid 
synthesis and myelination. Figure based on data from: Baslow and Guilfoyle (2009), 
Benarroch (2008), Hoshino and Kubota (2014) and Moffett et al. (2007). 
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